Treatment of rebound pulmonary hypertension: why not sildenafil?
Raja
Shahzad G
SG
D000280:Administration, Inhalation; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects; D011464:Epoprostenol / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D009569:Nitric Oxide / Q000008:administration & dosage / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D012008:Recurrence; D000068677:Sildenafil Citrate; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology; D013450:Sulfones; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
D000959:Antihypertensive Agents; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D009569:Nitric Oxide; D000068677:Sildenafil Citrate; D011464:Epoprostenol